Doxorubicin Hydrochloride

  (DOK-soh-ROO-bih-sin HY-droh-KLOR-ide)

This page contains brief information about doxorubicin hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s):		Adriamycin RDF
		Adriamycin PFS
FDA Approved:		Yes

Use in Cancer

Doxorubicin hydrochloride is approved to be used alone or with other drugs to treat:

• Acute lymphoblastic leukemia (ALL).

• Acute myelogenous leukemia (AML).

• Breast cancer. It is also used as adjuvant therapy for breast cancer that has spread to the lymph nodes after surgery.

• Gastric (stomach) cancer.

• Hodgkin lymphoma.

• Neuroblastoma.

• Non-Hodgkin lymphoma.

• Ovarian cancer.

• Small cell lung cancer.

• Soft tissue and bone sarcomas.

• Thyroid cancer.

• Transitional cell bladder cancer.

• Wilms tumor.

Doxorubicin hydrochloride is also being studied in the treatment of other types of cancer.

Doxorubicin hydrochloride is also available in a different form called doxorubicin hydrochloride liposome. For more information, see the Drug Information Summary for Doxorubicin Hydrochloride Liposome.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Doxorubicin Hydrochloride - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Clinical Trial Results: Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Anthracyclines Improve Survival for HER2-Positive, But Not HER2-Negative, Breast Cancer - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Positron Emission Tomography (PET) Can Strongly Predict Likelihood of Early Relapse in Hodgkin Lymphoma - Important clinical trial results for this drug, background information, and how the trial was done.

Clinical Trial Results: Less-Intense Chemotherapy Effective in Children with Intermediate-Risk Neuroblastoma - Important clinical trial results for this drug, background information, and how the trial was done.

Find Clinical Trials for Doxorubicin Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Back to Top